Figure 4

Purification of recombinant Kunitz-type inhibitors and their inhibition profiles against cysteine and serine proteases. (A) LDS-PAGE analysis of the recombinantly yeast-expressed F. hepatica KT inhibitors, rFhKT1.1 (lane 1); rFhKT1.1Leu15/Arg15 (lane 2); rFhKT1.3 (lane 3) and, rFhKT1Arg19/Ala19 (lane 4). M, molecular size markers. (B) Inhibitory activity (2 μM ) of rFhKT1.1 (red bars), rFhKT1Leu15/Arg15 (blue bars); rFhKT1.3 (green bars) and rFhKT1Arg19/Ala19 (black bars) against a range of cysteine proteases including F. hepatica cathepsin L1 (FhCL1), F. hepatica cathepsin L2 (FhCL2), F. hepatica cathepsin L3 (FhCL3), human cathepsin L (HsCL), human cathepsin K (HsCK), human cathepsin B (HsCB), human cathepsin S (HsCS) and the serine proteases trypsin and chymotrypsin. Inhibition is presented relative to the activity of each enzyme in the absence of inhibitors ± SD, visualised using GraphPad Software (v6 for Windows).